论文部分内容阅读
在3h内应用重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activator,rtPA)静脉溶栓的随机对照试验通常将老年卒中患者排除在外或者仅纳入少数老年患者。比较≥80岁与＜80岁卒中患者静脉rt- PA溶栓治疗的队列研究受到样本量较小的限制,而且得出了相互矛盾的结果。因此,瑞士巴塞尔大学医院神经内科的Engelter等进行了一项涉及所有此类研究的系统评价。
Randomized controlled trials of intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) within 3 hours often exclude elderly stroke patients or only a minority of elderly patients. Cohort studies comparing intravenous rt-PA thrombolysis in stroke patients ≥80 and <80 years of stroke were limited by the smaller sample size and yielded conflicting results. Therefore, Engelter et al., Department of Neurology, University Hospital Basel, Switzerland, conducted a systematic review of all such studies.